Citations

Showing 10 of 108119 citations.

Perioperative Glucose Control in Patients With Diabetes Undergoing Elective Surgery
Simha, Vinaya , Shah, Pankaj, Shah, Pankaj

Mayo Clinic

JAMA | January 9, 2019 | Volume: 321 | Issue: 4 | Pages: 399

10.1001/jama.2018.20922 | PMID 30615031 Get It

Curbing Unnecessary and Wasted Diagnostic Imaging
Oren, Ohad , Kebebew, Electron , Ioannidis, John P. A. , Ioannidis, John P A

Mayo Clinic

JAMA | January 9, 2019 | Volume: 321 | Issue: 3 | Pages: 245

10.1001/jama.2018.20295 | PMID 30615023 Get It

NASA-Task Load Index Differentiates Surgical Approach
Lowndes, Bethany R. , Blocker, Renaldo C., Nelson, Heidi , Law, Katherine E, Kelley, Scott R. , Law, Katherine E. , Larson, David W. , Hallbeck, M. Susan

Mayo Clinic

Annals of Surgery | January 9, 2019 | Volume: 271 | Issue: 5 | Pages: 906-912

10.1097/sla.0000000000003173 | PMID 30614878 Get It

Objective: Surgeon workload, or human “cost” of performing a procedure, is not well understood in light of emerging surgical technologies. This pilot study quantified surgeon workload for colorectal procedures and identified patient, surgeon, and procedural factors impacting workload. Summary Background Data: Innovative technologies and procedures in surgery have generally been promoted for the advancement of patient care. The resulting surgeon workload is poorly studied with little knowledge of the contributing factors impacting workload. Methods: Surgeons completed NASA-Task Load Index (NASA-TLX) questionnaires to self-assess workload following abdominopelvic colon and rectal procedures. Corresponding patient data were retrieved from the medical record. Descriptive statistics, correlations, and ANOVA were performed to compare surgeon and patient factors, procedure type, and surgical approach on workload overall and by subscales. Results: Seven attending surgeons rated 238 surgeries, of which 218 (92%) had corresponding patient data. Surgeon experience and patient demographics had inconsistent effects on workload. A statistically significant 3-way interaction was identified among disease process, procedure type, and surgical approach on workload (F(9, 146) = 2.17, P = 0.027), but was limited to open procedures for neoplasia and inflammatory bowel disease patients. Proctectomy and colectomy procedures compared across open, laparoscopic, and robotic approaches showed significant differences in overall workload and subscales, where the robotic procedures required significantly less mental demand, physical demand, and effort, than open or laparoscopic ( P < 0.05). Conclusions: Patient characteristics, disease process, and surgical experience had inconsistent effects on surgeon workload. Major differences in workload were identified for procedure type and surgical approach, where robotic procedures required less mental demand, physical demand, and effort.
Safety of Carotid Revascularization in Patients With a History of Coronary Heart Disease
Volkers, Eline J., Kappelle, L. Jaap, Becquemin, Jean‐Pierre , Borst, Gert J. de , Brown, Martin M. , Bulbulia, Richard , Calvet, David, Fraedrich, Gustav , Gregson, John , Hendrikse, Jeroen , Howard, George , Jansen, Olav , Roubin, Gary S., Bonati, Leo H. , Brott, Thomas G. , Mas, Jean‐Louis , Greving, Jacoba P. , Howard, George , Algra, Ale , Eckstein, Hans‐Henning , Halliday, Alison , Ringleb, Peter Arthur

Mayo Clinic

Stroke | January 9, 2019 | Volume: 50 | Issue: 2 | Pages: 413-418

10.1161/strokeaha.118.023085 | PMID 30621529 Get It

Background and Purpose— We investigated whether procedural stroke or death risk of carotid artery stenting (CAS) compared with carotid endarterectomy (CEA) is different in patients with and without history of coronary heart disease (CHD) and whether the treatment-specific impact of age differs. Methods— We combined individual patient data of 4754 patients with symptomatic carotid stenosis from 4 randomized trials (EVA-3S [Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis], SPACE [Stent-Protected Angioplasty Versus Carotid Endarterectomy], ICSS [International Carotid Stenting Study], and CREST [Carotid Revascularization Endarterectomy Versus Stenting Trial]). Procedural risk was defined as any stroke or death ≤30 days after treatment. We compared procedural risk between both treatments with Cox regression analysis, stratified by history of CHD and age (<70, 70–74, ≥75 years). History of CHD included myocardial infarction, angina, or coronary revascularization. Results— One thousand two hundred ninety-three (28%) patients had history of CHD. Procedural stroke or death risk was higher in patients with history of CHD. Procedural risk in patients treated with CAS compared with CEA was consistent in patients with history of CHD (8.3% versus 4.6%; hazard ratio [HR], 1.96; 95% CI, 0.67–5.73) and in those without (6.9% versus 3.6%; HR, 1.93; 95% CI, 1.40–2.65; P interaction =0.89). In patients with history of CHD, procedural risk was significantly higher after CAS compared with CEA in patients aged ≥75 (CAS-to-CEA HR, 2.78; 95% CI, 1.32–5.85), but not in patients aged <70 (HR, 1.71; 95% CI, 0.79–3.71) and 70 to 74 years (HR, 1.09; 95% CI, 0.45–2.65). In contrast, in patients without history of CHD, procedural risk after CAS was higher in patients aged 70 to 74 (HR, 3.62; 95% CI, 1.80–7.29) and ≥75 years (HR, 2.64; 95% CI, 1.52–4.59), but equal in patients aged <70 years (HR, 1.05; 95% CI, 0.63–1.73; 3-way P interaction =0.09). Conclusions— History of CHD does not modify procedural stroke or death risk of CAS compared with CEA. CAS might be as safe as CEA in patients with history of CHD aged <75 years, whereas for patients without history of CHD, risk after CAS compared with CEA was only equal in those aged <70 years.
Author response: Why we need to report more than 'Data were Analyzed by t-tests or ANOVA'
Weissgerber, Tracey L. , Valencia, Oscar A. Garcia , Garovic, Vesna D. , Milić, Nataša , Winham, Stacey J.

Mayo Clinic

No container title available | January 9, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.36163.021 Get It

Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)
Song, Mingyang , Hull, Mark A. , Shi, Qian , Giovannucci, Edward L. , Blarigan, Erin L. Van , Meyerhardt, Jeffrey A. , Zemla, Tyler J, Limburg, Paul J. , Meyerhardt, Jeffrey A , Shi, Qian , Song, Mingyang , Ou, Fang‐Shu , Zemla, Tyler , Alberts, Steven R. , Sinicrope, Frank A. , Chan, Andrew T.

Mayo Clinic

International Journal of Cancer | January 9, 2019 | Volume: 145 | Issue: 2 | Pages: 380-389

10.1002/ijc.32113 | PMID 30623420 Get It

Marine omega‐3 polyunsaturated fatty acids (MO3PUFAs) have anticancer properties and may improve colon cancer survival. However, it remains unknown whether the benefit differs by tumor molecular subtype. We examined data from a phase III randomized trial of FOLFOX or FOLFOX + cetuximab among 1,735 stage III colon cancer patients who completed a dietary questionnaire at enrollment. Multivariable hazard ratios and 95% confidence intervals (CIs) were calculated for the association between MO3PUFA and disease‐free survival (DFS) and overall survival according toKRASandBRAFV600Emutations and DNA mismatch repair (MMR) status. Higher MO3PUFA intake was associated with improved 3‐year DFS forKRASwild‐type tumors (77%vs. 73%; HR: 0.84; 95% CI: 0.67–1.05) but notKRAS‐mutant tumors (64%vs. 70%; HR: 1.30; 95% CI: 0.97–1.73;Pinteraction= 0.02). Similar heterogeneity was found by MMR (Pinteraction= 0.14): higher MO3PUFA was associated with better 3‐year DFS for tumors with deficient MMR (72%vs. 67%) but not proficient MMR (72%vs. 72%). No heterogeneity was found byBRAFV600Emutation. Similar findings were obtained for overall survival. In conclusion, we found a suggestive beneficial association between higher MO3PUFA intake and improved survival among stage III colon cancer patients with wild‐typeKRASand deficient MMR. Given the relatively small number of cases with tumor molecular assessments, further studies, preferably through pooled analyses of multiples cohorts, are needed to validate our findings.
Shedding Perspective on Extracellular Vesicle Biology in Diabetes and Associated Metabolic Syndromes
Javeed, Naureen , Javeed, Naureen

Mayo Clinic

Endocrinology | January 9, 2019 | Volume: 160 | Issue: 2 | Pages: 399-408

10.1210/en.2018-01010 | PMID 30624638 Get It

Shared Decision Making Rarely Happens for Lung Cancer Screening
Dobler, Claudia C.

Mayo Clinic

JAMA Internal Medicine | January 9, 2019 | Volume: 179 | Issue: 1 | Pages: 122

10.1001/jamainternmed.2018.6983 | PMID 30615081 Get It

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: “2019 Update on Diagnosis, Risk‐stratification, and Management”
Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | January 9, 2019 | Volume: 94 | Issue: 4 | Pages: 475-488

10.1002/ajh.25397 | PMID 30618061 Get It

Disease OverviewRing sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS), now classified under myelodysplastic syndromes with RS (MDS‐RS) and RARS with thrombocytosis (RARS‐T); now called myelodysplastic/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T).DiagnosisMDS‐RS is a lower‐risk MDS, with single or multilineage dysplasia (SLD/MLD), <5% bone marrow (BM) blasts and ≥ 15% BM RS (≥5% in the presence of SF3B1 mutations). MDS/MPN‐RS‐T, now a formal entity in the MDS/MPN overlap syndromes, has diagnostic features of MDS‐RS‐SLD, along with a platelet count ≥450 × 10(9)/L and large atypical megakaryocytes.Mutations and KaryotypeMutations in SF3B1 are seen in ≥80% of patients with MDS‐RS‐SLD and MDS/MPN‐RS‐T, and strongly correlate with the presence of BM RS; MDS/MPN‐RS‐T patients also demonstrate JAK2V617F, ASXL1, DNMT3A, SETBP1, and TET2 mutations. Cytogenetic abnormalities are uncommon in both.Risk stratificationMost patients with MDS‐RS‐SLD are stratified into lower‐risk groups by the revised‐IPSS. Disease outcome in MDS/MPN‐RS‐T is better than that of MDS‐RS‐SLD, but worse than that of essential thrombocythemia. Both diseases have a low risk of leukemic transformation.TreatmentAnemia and iron overload are complications seen in both and are managed similar to lower‐risk MDS and MPN. The advent of luspatercept, a first‐in‐class erythroid maturation agent will tremendously boost the ability to manage anemia. Aspirin therapy is reasonable in MDS/MPN‐RS‐T, especially in the presence of JAK2V617F, but the value of platelet‐lowering drugs remains uncertain.